Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS Clinical Trials Group Study (ACTG 149)
Article Abstract:
HIV patients with Hodgkin's disease may benefit from chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine. In a study of 21 such patients, 62% had a complete or partial response to chemotherapy.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma
Article Abstract:
A retrospective review of 26 patients with recurrent or primary resistant AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) and treated with either dexamethasone, cytosine arabinoside, and cisplatin (DHAP) or etoposide, methylprednisolone, cytosine arabinoside and cisplatin (ESHAP) has been carried out. High-dose cytosine-arabinoside and cisplatin regimens are investigated as salvage therapy for refractory or relapsed AIDS-NHL. No effective salvage regimen had been set forth for those with AIDS-NHL not responding to first-line chemotherapy including anthracycline.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
Article Abstract:
Low-dose m-BACOD chemotherapy appears to be as effective as standard-dose m-BACOD chemotherapy in the treatment of lymphomas and has fewer side effects. This was the conclusion of a study that randomly assigned 198 HIV-positive patients with non-Hodgkin's lymphoma to receive low-dose or standard-dose m-BACOD. m-BACOD consists of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone. Survival rates were similar in both groups but toxic effects were seen in only 51% of those in the low-dose group compared to 70% of those in the standard-dose group.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the nutrition for healthy living cohort
- Abstracts: Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection
- Abstracts: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection
- Abstracts: Chlamydial and gonococcal cervicitis in HIV-seropositive and HIV-seronegative pregnant women in Bangkok: prevalence, risk factors, and relation to perinatal HIV transmission
- Abstracts: Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection